skip to content


Issue No. 7 | February 8, 2008

News and Features


The Adult and Adolescent HIV Guidelines Working Group would like to hear your feedback on the latest revisions to the Adult and Adolescent Guidelines. Please send your comments with the subject line "Adult and Adolescent Comments" to by February 12, 2008.

Pediatric Formulation of Lamivudine Approved

On Thursday, February 7, the Food and Drug Administration approved a new formulation of the nucleoside reverse transcriptase inhibitor (NRTI), lamivudine, designed for use in pediatric patients with HIV. Lamivudine is now available as 150 mg scored tablets. Lamivudine labeling has been changed accordingly.

More information is available:

AIDSinfo: Pediatric Treatment Guidelines
AIDSinfo: Lamivudine drug fact sheet
AIDSinfo: Lamivudine clinical trials

DAIDS Appoints New Director

Dr. Carl W. Dieffenbach has been appointed Director of the Division of AIDS (DAIDS), a division of the National Institute of Allergy and Infectious Diseases (NIAID).

Dr. Dieffenbach began his work with NIAID in 1992 and served as the acting principal deputy director and acting director of DAIDS. He also served as a senior advisor to NIAID's Director, Dr. Anthony S. Fauci. In a press release announcing the appointment, Dr. Fauci recognized Dr. Dieffenbach's many accomplishments and critical contributions in furthering the understanding of HIV.

Check out the full story:

NIH: Full Press Release

Mouse Lymph Nodes Offer New Insight for Vaccine Research

Researchers from the National Institute of Allergy and Infectious Diseases (NIAID) have gained an important insight into the immune response to viral infection in mammals. Studying the lymph nodes of mice, researchers found that immune cells encounter viruses just inside the nodes, not deep within them, as previously believed. Of further significance, researchers were able to observe the interaction of viruses and immune cells inside a living organism.

This research will contribute to the efforts to create effective vaccines against viruses such as HIV.

More information is available: